Aptuit | Immunology and biomarkers

Immunology and biomarkers

A reputation for development

The multi-disciplinary scientists working at our Verona site for Drug Discovery and Development have grown an international reputation for quality work related to high-risk compounds. Their expertise supports and enables the development of biologics, including monoclonal antibodies and recombinant proteins.

Aptuit | Immunology and biomarkers

They also have exceptional experience in working with large molecules that are crucial in the development of therapeutic drugs for Oncology, arthritis, inflammatory diseases, metabolic disorders, psychiatry, neuro-degeneration and infections.

Our bioanalytical therapeutics capabilities can serve as part of an Aptuit INDiGO® program, an accelerated route to ‘First In Man’ that can be as short as 6 to 12 months - much less than the industry standard.

Particular areas of knowledge and expertise include blood factors, thrombolytic agents, hormones, hematopoietic growth factors, interferons, interleukin-based products, vaccines, monoclonal antibodies, tumor necrosis factor, therapeutic enzymes, oligonucleotides and innovative biosimilars and biobetters.

Our Pharmacokinetic/Toxicokinetic assays involve development, validation, sample analysis with applications in discovery and pre-clinical/clinical sample analysis:

  • Ligand Binding and Immunoassays for ELISA, DELFIA, RIA, EIA, CLIA, FIA, FRET and Alphascreen
  • Hybridization Assays
  • Enzyme Assays
  • Factor Assays
  • Other techniques such as NMR and LC-MS/MS

Our expert Consultancy in biotherapeutic strategy and regulatory support is based on the real-world expertise of experienced scientists.